Objective High-sensitivity cardiac troponin I (hs-cTnI) is a novel biomarker of myocardial injury and ischaemia. Our objective was to ascertain correlates of hs-cTnI and its incremental prognostic ...

Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at https://www.cytokinetics.com. The webcast replay will be ...

Cardiac troponin (cTn) is a highly specific biomarker of myocardial injury and is central to the diagnosis of acute myocardial infarction (AMI). By itself, however, cTn cannot identify the cause of ...

In recent years, cancer immunotherapy has made remarkable achievements. Immune checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the past decade. However, expanded ...

To date, research in basic science has disclosed a range of pathophysiological mechanisms of post-MI cardiac fibrosis, and many attractive inhibitors and antagonists have been developed based on the ...

Evidence for a final common pathway for disorders of the myocardium (pages 246 and 320–330). These studies further our understanding of the heart in health and disease, particularly in the ...

While the levels of miR-208b, miR-499 and miR-320a were significantly higher in patients with AMI compared with other diagnoses, none were able to out-perform cardiac Troponin T (cTnT) or ...

Dr Anne Peters discusses the focus on management of diabetes in this second video highlighting the 2025 Standards of Care in Diabetes.

ACS: Acute coronary syndrome; CV: Cardiovascular; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; TIA: Transient ischemic attack.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2025 it granted stock options to purchase an aggregate of 64,587 shares of common stock, 41,939 restricted stock units ...